Li Ding, Finley Stacey D
Department of Biomedical Engineering, University of Southern California, Los Angeles, CA, United States.
Department of Biomedical Engineering, Mork Family Department of Chemical Engineering and Materials Science, and Department of Biological Sciences, University of Southern California, Los Angeles, CA, United States.
Front Physiol. 2019 Jul 18;10:823. doi: 10.3389/fphys.2019.00823. eCollection 2019.
Tumor angiogenesis is regulated by pro- and anti-angiogenic factors. Anti-angiogenic agents target the interconnected network of angiogenic factors to inhibit neovascularization, which subsequently impedes tumor growth. Due to the complexity of this network, optimizing anti-angiogenic cancer treatments requires detailed knowledge at a systems level. In this study, we constructed a tumor tissue-based model to better understand how the angiogenic network is regulated by opposing mediators at the extracellular level. We consider the network comprised of two pro-angiogenic factors: vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF2), and two anti-angiogenic factors: thrombospondin-1 (TSP1) and platelet factor 4 (PF4). The model's prediction of angiogenic factors' distribution in tumor tissue reveals the localization of different factors and indicates the angiogenic state of the tumor. We explored how the distributions are affected by the secretion of the pro- and anti-angiogenic factors, illustrating how the angiogenic network is regulated in the extracellular space. Interestingly, we identified a counterintuitive result that the secretion of the anti-angiogenic factor PF4 can enhance pro-angiogenic signaling by elevating the levels of the interstitial and surface-level pro-angiogenic species. This counterintuitive situation is pertinent to the clinical setting, such as the release of anti-angiogenic factors in platelet activation or the administration of exogenous PF4 for anti-angiogenic therapy. Our study provides mechanistic insights into this counterintuitive result and highlights the role of heparan sulfate proteoglycans in regulating the interactions between angiogenic factors. This work complements previous studies aimed at understanding the formation of angiogenic complexes in tumor tissue and helps in the development of anti-cancer strategies targeting angiogenesis.
肿瘤血管生成受促血管生成因子和抗血管生成因子的调节。抗血管生成药物靶向血管生成因子的相互连接网络以抑制新血管形成,进而阻碍肿瘤生长。由于该网络的复杂性,优化抗血管生成癌症治疗需要系统层面的详细知识。在本研究中,我们构建了一个基于肿瘤组织的模型,以更好地理解血管生成网络在细胞外水平是如何被相反的介质调节的。我们考虑的网络由两种促血管生成因子:血管内皮生长因子(VEGF)和碱性成纤维细胞生长因子(FGF2),以及两种抗血管生成因子:血小板反应蛋白-1(TSP1)和血小板因子4(PF4)组成。该模型对肿瘤组织中血管生成因子分布的预测揭示了不同因子的定位,并表明了肿瘤的血管生成状态。我们探讨了促血管生成因子和抗血管生成因子的分泌如何影响这些分布,阐明了血管生成网络在细胞外空间是如何被调节的。有趣的是,我们发现了一个与直觉相反的结果,即抗血管生成因子PF4的分泌可以通过提高间质和表面水平的促血管生成物质的水平来增强促血管生成信号。这种与直觉相反的情况与临床情况相关,例如血小板激活时抗血管生成因子的释放或抗血管生成治疗中外源性PF4的给药。我们的研究为这一与直觉相反的结果提供了机制性见解,并强调了硫酸乙酰肝素蛋白聚糖在调节血管生成因子之间相互作用中的作用。这项工作补充了以往旨在理解肿瘤组织中血管生成复合物形成的研究,并有助于开发针对血管生成的抗癌策略。